BRAF and cancer: BRAF is a key signalling node in both pathological and physiological hypertrophy: inhibiting BRAF may be beneficial in pathological hypertrophy and the data have implications for repurposing of RAF inhibitors developed for cancer; inhibiting BRAF in physiological hypertrophy may result in increased fibrosis and using RAF inhibitors in this context could be detrimental in the longer term.